The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
Open accessAbstract
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The NetherlandsAbstract: Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.Keywords: alpha-glucosidase inhibitors, type 2 diabetes mellitus, impaired glucose tolerance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“With life-style modifi cations, a relative-risk reduction (RRR) in the progression to DM2 of 58% may be achieved (Tuomilehto et al 2001).”
BackgroundTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Beaglehole, R., & Yach, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14335-8 · Cited by 487
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335
Garratt, K. N., Brady, P. A., Hassinger, N. L., Grill, D. E., Terzic, A., & Holmes, D. R. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00557-9 · Cited by 332
Simpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235 · cited 1×
“…Group Diabetes Program suggesting an increased risk of cardiovascular morbidity with the use of tolbutamide were heavily criticized (Goldner et al 1971), sulphonylurea remained under the suspicion of unfavorable effects on cardiovascular disease up to now (Garratt et al 1999; Simpson et al 2006).”
BackgroundKnatterud, G. L. (1971) · JAMA · doi:10.1001/jama.217.6.777 · Cited by 227
Mg, G. (1971) · JAMA · doi:10.1001/jama.218.9.1400 · Cited by 221
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070038 · Cited by 219
Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068294 · Cited by 216
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
Johansen, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.33 · Cited by 186
Hoffmann, J., & Spengler, M. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00252-0 · Cited by 148
de Laar, F. A. V., Lucassen, P. L., Akkermans, R., van de Lisdonk, E. H., & Grauw, W. J. D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005061.pub2 · Cited by 119
Self-citationChiasson, J. L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2004) · Diabetologia · doi:10.1007/s00125-004-1409-4 · Cited by 101
Acarbose: Its Role in the Treatment of Diabetes Mellitus
Campbell, L. K., White, J. R., & Campbell, R. K. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603001110 · Cited by 90
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060.pub2 · Cited by 89
Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
Leahy, J. L. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79281-2 · Cited by 87
Fujita, H., Yamagami, T., & Ohshima, K. (2001) · Journal of Nutrition · doi:10.1093/jn/131.8.2105 · Cited by 76
Medicalisation in the 21st century: Introduction
Metzl, J. M., & Herzig, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60317-1 · Cited by 66
Kaiser, T., & Sawicki, P. T. (2004) · Diabetologia · doi:10.1007/s00125-003-1318-y · Cited by 62
Nathan, D. M. (2007) · Diabetes Care · doi:10.2337/dc06-2600 · Cited by 45
NHG-standaard Diabetes Mellitus type 2 (eerste herziening)
Rutten, G. E. H. M., Verhoeven, S., Heine, R. J., de Grauw, W. J. C., Cromme, P. V. M., Reenders, K., van Ballegooie, E., & Wiersma, T. (1999) · Data Archiving and Networked Services (DANS) · Cited by 40
The prevention of type 2 diabetes: general practitioner and practice nurse opinions.
Williams, R., Rapport, F., Elwyn, G. J., Lloyd, B., Rance, J. Y., & Belcher, S. (2004) · Europe PMC (PubMed Central) · Cited by 35
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060 · Cited by 33
Low‐dose acarbose does not delay digestion of starch but reduces its bioavailability
Wachters‐Hagedoorn, R. E., Priebe, M. G., Heimweg, J. A. J., Heiner, A. M., Elzinga, H., Stellaard, F., & Vonk, R. J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02115.x · Cited by 28
No evidence for a reduction of myocardial infarctions by acarbose
VANDELAAR, F., & Lucassen, P. L. B. J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.01.026 · Cited by 25
Cited by
The α-amylase and α-glucosidase inhibitory effects of Irish seaweed extracts
Lordan, S., Smyth, T. J., Soler-Vila, A., Stanton, C., & Ross, R. P. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.04.123 · Cited by 439
Etxeberria, U., de la Garza, A. L., Campión, J., Martínez, J. A., & Milagro, F. I. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.664134 · Cited by 395
Poovitha, S., & Parani, M. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1085-1 · Cited by 307
Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Mohamed Sham Shihabudeen, H., Hansi Priscilla, D., & Thirumurugan, K. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-46 · Cited by 163
Metadata
- Authors
- Laar, F.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-12
- Volume
- Volume 4
- Issue
- 6
- Pages
- 1189-1195
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W1479698458
- Cited by
- 360
- References
- 44
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.